Unbiased headlines. Facts, not spin.
Unbiased Headlines is an independently owned news organization. We bring you the facts, not opinions, written fresh from 110+ named sources. Sources linked so you can verify it yourself.
Pelacarsen Fails on Heart Events, Older Adults Who Quit Statins Had More Events, Myqorzo Label Decision Falls Due Nov. 14

Since Cytokinetics reported third-quarter results on Nov. 4, a cluster of heart-drug developments has landed, from the American Heart Association's Scientific Sessions in Chicago to the FDA's weekly recall report. Some are failures, some are judgment calls, and one is still waiting on a regulator.
A long-awaited Lp(a) drug does not work
Pelacarsen was supposed to be the first drug to prove that lowering lipoprotein (a), or Lp(a), cuts heart attacks and strokes. It did not hit its main goal of reducing major cardiovascular events.
Dr. Steven Nissen, a preventive cardiologist at the Cleveland Clinic, presented the results at the AHA conference. He and colleagues spent seven years testing the drug in 8,350 people who had already had a cardiovascular event.
"It wasn't a near miss. It just didn't have an effect on outcomes," Nissen told CNN. He said the result was "uniformly expected to be favorable" and that the audience would be surprised.
Novartis, which funded the development, has decided to abandon the drug, CNN reported. Lp(a) is an inherited, sticky, protein-wrapped fat. The American Heart Association says people with the highest blood levels are two to four times more likely to have a heart attack than people with the lowest. Nissen said more than a billion people have the disorder.
His own read: the failure may force cardiologists to rethink Lp(a)'s causal role in heart disease. That is Nissen's assessment, and the question is now open.
Stopping statins after 70: a closer call than the headline
A randomized trial presented Nov. 7 at the same conference, and published in The New England Journal of Medicine, tested what happens when older adults stop statins. Researchers from the University of Bern, the University of California, San Francisco, and other institutions enrolled 1,880 adults aged 70 and older. All were taking statins to prevent a first heart attack or stroke, and all had at least two chronic conditions.
Half stopped. Half continued.
After two years, the added risk from stopping fell within the limit the researchers set in advance. That does not mean the risk was zero. Over the full follow-up, about two years for the typical participant and up to four for some, about 13% of those told to stop had a heart attack, an ischemic stroke or died from any cause. In the continuing group it was about 9%.
The study's safety monitoring board recommended that participants assigned to stop discuss restarting with their care team, according to the American College of Cardiology.
There was no meaningful difference between the groups in quality of life, muscle pain, falls or loss of muscle mass and strength. Dr. Christopher Kelly, a UNC Health cardiologist, stressed that continuing statins did not worsen muscle pain or quality of life in the trial. He said the decision should be individualized, based on overall health and expected lifespan.
The trial's design and its raw numbers point in different directions. The prespecified margin was met at two years. The event gap, 13% versus 9%, is what the monitoring board's restart advice responded to.
Metoprolol recall
Separately, the FDA published a Class II recall of a metoprolol product in its Nov. 11 enforcement report. A New Jersey-based drug company is recalling thousands of bottles because of the "presence of foreign tablets/capsules." The notice gave no further detail.
The recalled batch is 2611C065A1, with an expiration date of May 2028. The recall was initiated Oct. 27, 2026, and customers were notified by letter. The tablets were distributed nationwide.
The FDA defines Class II as a situation where exposure "may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." The agency says consumers can generally keep taking the medicine in Class II recalls unless the company says otherwise, and warns that stopping may be more harmful. The company listed no other instructions.
Metoprolol is a beta blocker used for high blood pressure, angina and to lower the risk of repeat heart attacks. ClinCalc estimates more than 58 million prescriptions in 2024 and nearly 14.6 million users.
Myqorzo's label decision is due today
The FDA is expected to rule by today, Nov. 14, on a supplemental application from Cytokinetics to update the label of Myqorzo (aficamten). The drug has been approved since December 2025 for adults with symptomatic obstructive hypertrophic cardiomyopathy. The update would add results from the Phase 3 MAPLE-HCM trial, which compared Myqorzo alone with metoprolol alone. The 2024 AHA/ACC guideline recommends beta blockers like metoprolol first for obstructive HCM symptoms.
Cytokinetics has not said what label wording it is seeking, and no decision had been announced as of this writing. Because the drug is already sold, an approval changes the label, not patient access. A complete response letter would mean the FDA declined to approve the application in its current form.
The company's numbers give context. Cytokinetics reported $44.5 million in Myqorzo net product revenue for the third quarter and about $1.6 billion in cash, cash equivalents and investments as of Sept. 30. CEO Robert Blum said the company has presented and published ACACIA-HCM, "the first positive Phase 3 clinical trial in nHCM," and is moving to seek approvals in non-obstructive disease.
The company plans to submit a supplemental NDA for non-obstructive HCM in the fourth quarter of 2026 and a Type II variation in the European Union in early 2027. What the FDA decides on the MAPLE-HCM label will be the first regulatory read on how Myqorzo can be described against the standard first-line drug.
Sources used for this briefing
7 links from 7 independent newsrooms (syndicated copies of the same report count once)
These are the sources it draws on, linked so you can verify.